Can Kisqali® (Ribociclib) effectively target triple-negative breast cancer? A computational insight on potential mechanisms and therapeutic strategies
Abstract Triple-negative breast cancer (TNBC), which represents 15–20% of all breast cancers, is a highly aggressive subtype distinct by the absence of estrogen, progesterone, and HER2 receptors, with few targeted therapies available. Present study explores Kisqali® (Ribociclib)'s therapeutic p...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-05-01
|
| Series: | Discover Chemistry |
| Online Access: | https://doi.org/10.1007/s44371-025-00161-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|